Wang Guiqun, Seidler Nico J, Röhm Sandra, Pan Yufeng, Liang Xiaojun Julia, Haarer Lisa, Berger Benedict-Tilman, Sivashanmugam Saran Aswathaman, Wydra Valentin R, Forster Michael, Laufer Stefan A, Chaikuad Apirat, Gehringer Matthias, Knapp Stefan
Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438, Frankfurt am Main, Germany.
Structure Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, Germany.
Angew Chem Int Ed Engl. 2025 Feb 17;64(8):e202419736. doi: 10.1002/anie.202419736. Epub 2025 Jan 13.
Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for highly related kinases is selectivity. Unlike their non-covalent counterparts, covalent inhibitors offer the advantage of selectively targeting structurally similar kinases by modifying specific protein side chains, particularly non-conserved cysteines. Previously, covalent fragment screens yielded potent and selective inhibitors for individual kinases such as ERK1/2 but have not been applied to the broader kinome. Furthermore, many of the accessible cysteine positions have not been addressed so far. Here, we outline a generalizable approach to sample ATP-site cysteines with fragment-like covalent inhibitors. We present the development of a kinase-focused covalent fragment library and its systematic screening against a curated selection of 47 kinases, with 60 active site-proximal cysteines using LC/MS and differential scanning fluorimetry (DSF) assays, followed by hit validation through various complementary techniques. Our findings expand the repertoire of targetable cysteines within protein kinases, provide insight into unique binding modes identified from crystal structures and deliver isoform-specific hits with promising profiles as starting points for the development of highly potent and selective covalent inhibitors.
蛋白激酶是重要的药物靶点,但在500多种人类激酶中,仅针对一小部分开发出了特异性抑制剂。设计针对高度相关激酶的抑制剂时,一个主要挑战是选择性。与非共价抑制剂不同,共价抑制剂具有通过修饰特定蛋白质侧链(特别是非保守半胱氨酸)来选择性靶向结构相似激酶的优势。此前,共价片段筛选产生了针对个别激酶(如ERK1/2)的强效和选择性抑制剂,但尚未应用于更广泛的激酶组。此外,许多可及的半胱氨酸位置迄今尚未得到研究。在此,我们概述了一种用类片段共价抑制剂对ATP位点半胱氨酸进行取样的通用方法。我们展示了一个聚焦激酶的共价片段文库的开发过程,以及使用液相色谱/质谱(LC/MS)和差示扫描荧光法(DSF)分析,针对精心挑选的47种激酶、60个活性位点近端半胱氨酸进行的系统筛选,随后通过各种互补技术进行命中验证。我们的研究结果扩展了蛋白激酶中可靶向半胱氨酸的范围,深入了解了从晶体结构中确定的独特结合模式,并提供了具有前景的亚型特异性命中物,作为开发高效和选择性共价抑制剂的起点。